FBRX · As filed with the SEC
Forte Biosciences income statement, by fiscal year
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|---|
| Operating expenses: | |||
| Research and development | 57,647,000 | 20,714,000 | 21,862,000 |
| Research and development - related party | 600,000 | 479,000 | — |
| General and administrative | 12,410,000 | 15,409,000 | 10,624,000 |
| Total operating expenses | 70,657,000 | 36,602,000 | 32,486,000 |
| Loss from operations | (70,657,000) | (36,602,000) | (32,486,000) |
| Interest income | 2,715,000 | 1,314,000 | 1,124,000 |
| Other expense, net | (396,000) | (190,000) | (114,000) |
| Total other income, net | 2,319,000 | — | — |
| Net loss before taxes | (68,338,000) | — | — |
| Income tax expense | 1,037,000 | — | — |
| Net loss | (69,375,000) | (35,478,000) | (31,476,000) |
| Net loss per share - basic | (4.71) | (12.17) | (24.92) |
| Net loss per share - diluted | (4.71) | (12.17) | (24.92) |
| Weighted average shares and pre-funded warrants outstanding, basic | 14,717,734 | 2,915,894 | 1,262,840 |
| Weighted average shares and pre-funded warrants outstanding, diluted | 14,717,734 | 2,915,894 | 1,262,840 |
| Comprehensive Loss: | |||
| Net loss | (69,375,000) | (35,478,000) | (31,476,000) |
| Unrealized (loss) gain on available-for-sale securities, net | (8,000) | 7,000 | 4,000 |
| Comprehensive loss | (69,383,000) | (35,471,000) | (31,472,000) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.